Krystal Biotech KRYS - オプションチェーン | ADVFN

US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Krystal Biotech Inc (KRYS)
Krystal Biotech Inc (KRYS) オプション

Krystal Biotech Inc (KRYS)

153.24

-2.51

(-1.61%)

終了 2月18日 6:00AM

153.24

-0.37

(-0.24%)

取引時間後: 6:03AM

KRYS ライブオプションフロー

オプションコール

行使価格	買値	売値	前回の価格	中間価格	前日比	前日比 %	出来高	建玉	最終取引
105.00	46.50	50.40	0.00	48.45	0.00	0.00 %	0	0	-
110.00	40.00	40.00	40.00	40.00	0.00	0.00 %	0	0	-
115.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
120.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
125.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
130.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
135.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
140.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
145.00	15.50	15.50	15.50	15.50	0.00	0.00 %	0	2	-
150.00	6.00	6.00	6.00	6.00	0.00	0.00 %	0	1,002	-
155.00	5.50	9.70	7.43	7.60	2.77	59.44 %	65	9	2025/2/15
160.00	5.78	5.78	5.78	5.78	0.00	0.00 %	0	12	-
165.00	3.92	3.92	3.92	3.92	0.00	0.00 %	0	35	-
170.00	1.10	6.00	6.00	3.55	0.00	0.00 %	0	151	-
175.00	2.10	2.10	2.10	2.10	0.00	0.00 %	0	15	-
180.00	0.65	0.65	0.65	0.65	0.00	0.00 %	0	20	-
185.00	0.05	4.00	1.20	2.025	0.00	0.00 %	0	16	-
190.00	0.05	2.90	0.50	1.475	0.00	0.00 %	0	28	-
195.00	1.91	1.91	1.91	1.91	0.00	0.00 %	0	17	-
200.00	0.61	0.61	0.61	0.61	0.00	0.00 %	0	35	-

個人投資家向けのプロ仕様のツール。

プレミアム

オプションプット

行使価格	買値	売値	前回の価格	中間価格	前日比	前日比 %	出来高	建玉	最終取引
105.00	1.75	1.90	1.75	1.825	0.00	0.00 %	0	1	-
110.00	0.00	4.70	0.00	0.00	0.00	0.00 %	0	0	-
115.00	3.00	3.00	3.00	3.00	0.00	0.00 %	0	1	-
120.00	0.00	4.80	0.00	0.00	0.00	0.00 %	0	0	-
125.00	0.10	5.00	0.98	2.55	-0.71	-42.01 %	65	1	2025/2/15
130.00	0.30	5.00	1.60	2.65	0.00	0.00 %	0	1,003	-
135.00	0.50	5.00	0.00	2.75	0.00	0.00 %	0	0	-
140.00	1.65	1.65	1.65	1.65	0.00	0.00 %	0	10	-
145.00	3.50	7.20	2.75	5.35	0.00	0.00 %	0	1	-
150.00	7.22	7.22	7.22	7.22	0.00	0.00 %	0	1,001	-
155.00	7.60	12.00	7.50	9.80	3.36	81.16 %	1	4	2025/2/14
160.00	3.80	3.80	3.80	3.80	0.00	0.00 %	0	504	-
165.00	14.50	18.50	4.30	16.50	0.00	0.00 %	0	1	-
170.00	18.00	22.50	14.20	20.25	0.00	0.00 %	0	5	-
175.00	22.50	26.50	14.00	24.50	0.00	0.00 %	0	3	-
180.00	26.50	31.00	23.85	28.75	0.00	0.00 %	0	22	-
185.00	22.84	22.84	22.84	22.84	0.00	0.00 %	0	0	-
190.00	36.00	40.00	29.16	38.00	0.00	0.00 %	0	1	-
195.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-
200.00	0.00	0.00	0.00	0.00	0.00	0.00 %	0	0	-

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
JTAIJet AI Inc	US$ 6.02 (133.33%)	104.48M
SRMSRM Entertainment Inc	US$ 0.6999 (95.50%)	254.39M
WRDWeRide Inc	US$ 31.4877 (83.39%)	21.07M
INLFINLIF Limited	US$ 16.27 (80.58%)	7.68M
MBRXMoleculin Biotech Inc	US$ 2.1201 (66.94%)	136.66M
BLACBellevue Life Sciences Acquisition Corporation	US$ 3.08 (-56.31%)	425.19k
BLACUBellevue Life Sciences Acquisition Corporation	US$ 3.36 (-52.68%)	5.21k
CSAICloudastructure Inc	US$ 19.0001 (-49.58%)	1.01M
NEXNNexxen International Ltd	US$ 10.30 (-49.16%)	160.99k
BSLKBolt Projects Holdings Inc	US$ 0.6626 (-46.13%)	13.07M
CNSPCNS Pharmaceuticals Inc	US$ 0.1415 (31.26%)	489.28M
MGOLMGO Global Inc	US$ 0.7176 (-15.08%)	417.31M
SRMSRM Entertainment Inc	US$ 0.6999 (95.50%)	254.39M
INTCIntel Corporation	US$ 23.60 (-2.20%)	230.26M
NVDANVIDIA Corporation	US$ 138.85 (2.63%)	194.99M

Monksdream

Monksdream 4月前

KRYS. Under $200

Monksdream

Monksdream 7月前

KRYS new 52 week high

Monksdream

Monksdream 9月前

KRYS 10Q due 5/6

Monksdream

Monksdream 10月前

Monksdream

Monksdream 11月前

KRYS new 52 week high

Monksdream

Monksdream 2年前

From Cathie Wood
A Novel Gene Therapy Promises Relief For A Rare Genetic Skin Disorder
ARK Invest_Illustration_Pierce Jamieson_Final_Circle 400 px By Pierce Jamieson | @PierceARK
Research Associate
Recently, the US Food and Drug Administration (FDA) approved Krysta Biotech’s (KRYS) groundbreaking advance1 in gene therapy, Vyjuvek, to treat wounds in patients suffering from dystrophic epidermolysis bullosa (DEB), a rare and serious genetic skin disorder caused by mutations in the collagen Type VII alpha 1 chain (COL7A1) gene. As the first FDA-approved gene therapy for DEB, Vyjuvek is a significant breakthrough.

Vyjuvek uses a genetically modified HSV-1 to deliver normal copies of the COL7A1 gene to wounds, restoring the integrity of the skin with fibrils that hold skin layers together. Treated with Vyjuvek, 65% of wounds closed completely.

wiredawg

wiredawg 3年前

Moving nicely today...

wiredawg

wiredawg 3年前

Looking at the few posts here there seems to be no real commitment here...any thoughts on KRYS? Hype or something brewing?

wiredawg

wiredawg 3年前

In the last 3 months, 5 ranked analysts set 12-month price targets for KRYS. The average price target among the analysts is $125.00. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price. High $140 Low $111

wiredawg

wiredawg 3年前

30 Nov Tues releases this PR during evening after market close:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-pricing-200-million-public-offering

wiredawg

wiredawg 3年前

29 Nov Mon after market closes release this PR:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-proposed-200-million-public-offering

wiredawg

wiredawg 3年前

29 Nov Monday pre-market news release, great move pre-market approx 7am and so far holding fairly well:

https://ir.krystalbio.com/news-releases/news-release-details/krystal-biotech-announces-positive-topline-results-gem-3-pivotal

wiredawg

wiredawg 3年前

This caught my eye on Monday, the huge move off the PR...I'm guessing here saw the same. Any real thoughts regarding the company and this PR. I have not gotten a chance to dig into it. Hoping to have somm DD done over the weekend.

wiredawg

wiredawg 3年前

Holding well so far, why the pretty hard drop?

wiredawg

wiredawg 3年前

Why are you surprised? Serious question, not being impudent...

rynlrt

200 million dollar offering. Won't be surprised to see it drop pretty hard when the market opens

Fofo812

Fofo812 3年前

Surprised it held up this long

crudeoil24

crudeoil24 3年前

Large tutes holdings. Some taking huge gains before years end.

rynlrt

Not sure this kind of gain is sustainable. May see a big pullback

Fofo812

Fofo812 3年前

crudeoil24

crudeoil24 3年前

Krystal Biotech shares are trading higher after the company announced its GEM-3 trial met its primary endpoint.

Trophy

Krystal Biotech

DIIN25F27 - 07/2025

ProShares Bitcoin and Et...

First Trust Intermediate...

iShares US Home Construc...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約